DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Healthcare
Author Program NEWCreate Narrative
CLOV logo

Clover Health Investments, Corp. Stock Price

NasdaqGS:CLOV Community·US$2.6b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 113 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

CLOV Share Price Performance

US$4.82
1.68 (53.50%)
​
US$5.17
Fair Value
US$4.82
1.68 (53.50%)
6.7% undervalued intrinsic discount
US$5.17
Fair Value
Price US$4.82
AnalystConsensusTarget US$5.17
AnalystLowTarget US$5.00
AnalystHighTarget US$6.00
Mon, 10 Aug 26
Fair ValueUS$5.17
Share Pricen/a

CLOV Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$5.17 6.7% undervalued intrinsic discount

Margin Pressures and Healthcare Reforms Will Influence Future Medicare Advantage Dynamics

1users have liked this narrative
0users have commented on this narrative
47users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$5 3.6% undervalued intrinsic discount

Rising Costs And Regulation Will Erode Medicare Advantage Profitability

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$6 19.7% undervalued intrinsic discount

Digital Healthcare And Medicare Advantage Will Unlock Long-term Opportunities

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
CLOV logo
Clover Health Investments
6.7% undervalued intrinsic discount

Margin Pressures and Healthcare Reforms Will Influence Future Medicare Advantage Dynamics

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 10 Aug
Read Narrative
CLOV logo
Clover Health Investments
19.7% undervalued intrinsic discount
Updated

Digital Healthcare And Medicare Advantage Will Unlock Long-term Opportunities

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 10 Sep
Read Narrative
CLOV logo
Clover Health Investments
3.6% undervalued intrinsic discount

Rising Costs And Regulation Will Erode Medicare Advantage Profitability

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 24 Aug
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystHighTarget
CLOV logo

CLOV: Medicare Advantage Scale And Profitability Shift Will Drive Next Rerating

Fair Value: US$6 19.7% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
CLOV logo

CLOV: Cleaner 2026 Earnings Delivery Will Likely Unlock Further Upside

Fair Value: US$5 3.6% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
CLOV logo

CLOV: Sector Rebound And Regulatory Probes Will Shape Returns From Here

Fair Value: US$5.17 6.7% undervalued intrinsic discount
47 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Flawless balance sheet and undervalued.

1 Risk
4 Rewards
View Full Analysis

Clover Health Investments, Corp. Key Details

US$2.5b

Revenue

US$2.0b

Cost of Revenue

US$459.1m

Gross Profit

US$477.5m

Other Expenses

-US$18.4m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-0.035
18.54%
-0.74%
0%
View Full Analysis

About CLOV

Founded
2014
Employees
724
CEO
Andrew Toy
WebsiteView website
www.cloverhealth.com

Clover Health Investments, Corp. provides medicare advantage plans in the United States. The company offers preferred provider organization and health maintenance organization plans to medicare-eligible individuals. It also operates Clover Assistant, a software platform for physicians to detect, identify, and manage chronic diseases. The company was founded in 2014 and is based in Wilmington, Delaware.

Recent CLOV News & Updates

User avatar
Narrative Update • Sep 10

CLOV: Medicare Advantage Scale And Profitability Shift Will Drive Next Rerating

Analysts have raised their price target on Clover Health Investments from $5.50 to $6.00, citing new coverage that emphasizes the Medicare Advantage focus, the Clover Assistant software platform, and the non delegated risk model as key factors in their updated assessment. Analyst Commentary Bullish analysts covering Clover Health Investments are highlighting the stock as a way to gain exposure to the Medicare Advantage market at what they view as an attractive valuation.
User avatar
Narrative Update • Aug 24

CLOV: Cleaner 2026 Earnings Delivery Will Likely Unlock Further Upside

Analysts have raised their price targets for Clover Health Investments to a range of about $4.75 to $5.50. They cite refreshed models ahead of earnings, a stronger sector backdrop since March, and an expectation that a cleaner upcoming quarter will be important for any further share price progress.

Recent updates

No updates

Clover Health Investments, Corp. Competitors

SOLV logo

Solventum

Symbol: NYSE:SOLV
Market cap: US$14.9b
PEN logo

Penumbra

Symbol: NYSE:PEN
Market cap: US$12.5b
BAX logo

Baxter International

Symbol: NYSE:BAX
Market cap: US$12.3b
BTSG logo

BrightSpring Health Services

Symbol: NasdaqGS:BTSG
Market cap: US$12.2b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide